AskMed

SLE Disease: Criteria, Organ Involvement and Monitoring

SLE disease, short for systemic lupus erythematosus, is a chronic autoimmune disease in which autoantibodies and immune cells inflame tissues and, over time, can permanently damage organs. Almost any organ can be involved: the skin, joints, kidneys, blood cells, the linings of the heart and lungs, and the brain and nerves. Adult women are affected about nine times as often as men, and 15 to 20% of people develop it in childhood. Because two people with SLE can look completely different, specialists rely on structured tools: the 2019 EULAR/ACR classification criteria, antibody and complement tests, organ-specific work-up and validated scores for activity, flares and damage. This guide covers each one, following the 2026 British Society for Rheumatology (BSR) guideline and EULAR recommendations, with every figure linked to its source.

Each tool comes from a different paper or guideline, and the details that change a decision, such as which items count or which assay qualifies, sit in long tables. AskMed is a medical question app made for doctors, nurses, pharmacists, medical students and researchers. Instead of answering from memory, it searches journals, clinical guidelines and drug labels first, then writes an answer with a link after every claim. Ask it how many points joint involvement, low C3 and C4 and a positive anti-dsDNA add up to under the 2019 criteria, and it sets out each domain weight with the criteria paper one tap away.

Check an SLE criteria question against the source in AskMed:

What kind of disease is SLE?

Systemic lupus erythematosus (SLE) is a lifelong, multi-system autoimmune disease that causes inflammation and then damage in organs including the skin, joints, kidneys, brain, lungs and heart, as a 2025 review in Clinical Medicine by rheumatologists in Leeds describes it. Its exact cause is unknown: genetic, environmental, immunological and hormonal factors all appear to play a part, and its course typically alternates between relapses and periods of remission on treatment. The immunological hallmark is antinuclear antibodies (ANA), found in 95 to 99% of people with SLE. The disease is uncommon, affecting about 1 in 1,000 adults in the UK, and is seen most often in people of African-Caribbean and South Asian ancestry, in whom it also tends to be more severe, with more kidney involvement. SLE is not a benign condition: mortality is about three times that of the general population in adult-onset disease and 18 times in childhood-onset disease, and it is highest in the first year after diagnosis.

Diagnosing SLE and classifying it are different tasks. The 2026 BSR guideline says SLE should be diagnosed by clinicians experienced in its management, from a combination of clinical, laboratory and immunological features attributable to SLE, and that the SLICC 2012 or EULAR/ACR 2019 classification criteria may be used as a guide but not as diagnostic criteria. Classification criteria are built to group patients for research with high specificity, so they leave out features that are common but less specific, such as Raynaud phenomenon and anti-Ro antibodies, and rare ones such as lupus hepatitis, lupus enteritis, shrinking lung syndrome and myocarditis. Getting to a diagnosis takes time: the Clinical Medicine review reports a delay from first symptoms of as long as 6.4 years, and the BSR guideline asks that people with a strong suspicion of new SLE be seen by a specialist within three weeks.

For the symptoms, types and everyday side of the condition, see our guide to lupus. This page stays with how specialists define, test and follow SLE.

How do the 2019 EULAR/ACR classification criteria work?

The 2019 EULAR/ACR classification criteria for SLE, developed jointly by EULAR and the American College of Rheumatology and published by Aringer and colleagues, use a positive ANA at a titre of at least 1:80 on HEp-2 cells, or an equivalent positive test, at least once, as an obligatory entry criterion. Additive criteria are then grouped into 7 clinical domains (constitutional, haematologic, neuropsychiatric, mucocutaneous, serosal, musculoskeletal and renal) and 3 immunological domains (antiphospholipid antibodies, complement proteins and SLE-specific antibodies), and each item is weighted from 2 to 10 points. Only the highest-weighted item in each domain counts, the items do not need to be present at the same time, and an item counts only if SLE is its most likely explanation. A person with 10 or more points and at least one clinical criterion is classified as having SLE. In the validation cohort of 1,270 people, the criteria had a sensitivity of 96.1% and a specificity of 93.4%, against 82.8% and 93.4% for the ACR 1997 criteria.

  1. Entry: ANA of at least 1:80 on HEp-2 cells, or an equivalent positive test, at least once. Without it, the criteria are not applied.
  2. Attribute: count an item only if there is no more likely explanation than SLE, such as infection, a drug or another disease.
  3. Score: in each of the 10 domains, take only the highest-weighted item; items need not occur at the same time.
  4. Classify: 10 points or more, with at least one clinical item, classifies SLE.
How a case is scored under the 2019 EULAR/ACR classification criteria (Aringer et al., 2019; Scopes and Md Yusof, 2025).

These are all the items and their points, with the definitions from the criteria paper:

Two consequences follow from the weights. Class III or IV lupus nephritis on biopsy is worth 10 points on its own, so with a positive ANA it is enough to classify SLE; in the expert Delphi survey behind the criteria, 85% of experts said they would classify SLE on kidney pathology alone. And because points do not stack within a domain, oral ulcers add nothing to someone who already has acute cutaneous lupus. The ANA entry rule has a cost the authors acknowledge: people who are persistently ANA negative cannot be classified, a small group they put high on the research agenda.

Which antibody and laboratory tests matter in SLE?

The core laboratory tests in SLE are the ANA screen, the more specific anti-dsDNA and anti-Smith (anti-Sm) antibodies, complement C3 and C4, antiphospholipid antibodies, a full blood count and urine tests. The ANA is the sensitive screen: the 2026 BSR guideline notes that it is present in 95 to 99% of people with SLE at some point, so a negative result makes SLE unlikely, but about 5 to 10% of healthy adults also test positive, far more than the number who have SLE. In one Leeds clinic, only 17% of ANA-positive referrals from primary care turned out to have SLE or another connective tissue disease. For that reason the BSR recommends testing ANA only when there is reasonable clinical suspicion, and following a positive result with anti-dsDNA, extractable nuclear antigen antibodies (which include anti-Sm) and C3 and C4, because anti-dsDNA, anti-Sm and low complement are highly supportive of SLE in someone with relevant symptoms.

The assay matters too. Many laboratories now screen with ELISA or multiplex bead assays rather than immunofluorescence, and the BSR guideline warns that these can give false-positive results in up to 7% of tests, mostly at low titres, so low-level positives are often checked by immunofluorescence.

How is lupus nephritis found and classified?

Lupus nephritis is kidney inflammation caused by SLE and one of its most serious organ manifestations. The US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) says that as many as 5 in 10 adults and 8 in 10 children with lupus will have kidney disease, and that 10 to 30% of people with lupus nephritis develop kidney failure. It is more common in men with lupus than in women, and in African American, Hispanic and Asian American people. Lupus nephritis rarely announces itself: the symptoms NIDDK lists, foamy urine, swelling of the legs, feet or ankles and high blood pressure, are easy to miss, so it is usually found by testing. That is why the 2026 BSR guideline asks for urinalysis and blood pressure at every visit, and for renal function with an estimate of proteinuria whenever the disease is active. Proteinuria above 0.5 g in 24 hours, measured by a 24-hour collection or a spot protein-to-creatinine ratio, is itself a criterion item.

Kidney function is followed with serum creatinine and an estimated GFR, which the eGFR calculator works out from a creatinine result. The BSR guideline recommends a timely kidney biopsy as part of the initial diagnosis, because the histological class shapes treatment, and care in a combined rheumatology and renal service.

The biopsy classes

The 2018 revision of the International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification removed the old IV-S and IV-G subdivisions and replaced the "active" and "chronic" labels with modified NIH activity and chronicity indices to be applied to every class. Treatment is chosen by class and risk: for new or relapsing class III or IV nephritis, the BSR guideline offers glucocorticoids and hydroxychloroquine plus a mycophenolic acid analogue combined with obinutuzumab, a calcineurin inhibitor (voclosporin or tacrolimus) or belimumab. The EULAR/ERA-EDTA recommendations set the target as complete response, proteinuria below 0.5 to 0.7 g in 24 hours with near-normal GFR, by 12 months.

The kidney is where guideline detail matters most, and the BSR guideline itself points to the KDIGO, EULAR, ACR and SHARE guidelines for the specifics of proteinuria monitoring and biopsy. Ask AskMed when persistent proteinuria in SLE should lead to a kidney biopsy, or how a class IV result with a high chronicity index changes the choice of treatment, and the answer sets out what each current guideline says, each statement linked to the recommendation it comes from.

Look up a lupus nephritis question in AskMed:

How does SLE affect the blood and the nervous system?

SLE affects the blood mainly through autoantibodies that destroy or suppress blood cells, and the nervous system through a wide range of syndromes, from seizures to psychosis, that are often hard to attribute. The 2019 criteria define the blood items precisely: leukopenia is a white cell count below 4,000/mm³, thrombocytopenia a platelet count below 100,000/mm³, and autoimmune haemolysis needs evidence of haemolysis, such as reticulocytosis, low haptoglobin, raised indirect bilirubin or raised LDH, together with a positive direct antiglobulin (Coombs) test. For the nervous system, the American College of Rheumatology's 1999 nomenclature gives case definitions for 19 neuropsychiatric lupus syndromes affecting the brain, spinal cord and peripheral nerves. In both areas the key question is the one the criteria ask: is SLE really the cause? A low platelet count can come from a drug or an infection, and confusion from infection, metabolic upset or medicines, so other causes are looked for first.

Blood

Low blood counts need the same attribution step as any criterion item, and anaemia in particular has many causes besides SLE (see our guide to anemia). The BSR guideline names intravenous immunoglobulin as an option for severe autoimmune thrombocytopenia attributed to SLE, with thrombopoietin receptor agonists considered with haematologists in refractory cases. It also flags a rare emergency: haemophagocytic lymphohistiocytosis, or macrophage activation syndrome, a hyperinflammatory state with high fever, falling blood counts, high ferritin, raised liver enzymes and triglycerides, and coagulopathy. Data from England show a crude one-year mortality of 50%, so in SLE with unexplained fever and falling counts it should be considered alongside infection and flare, investigated with the H-score, and treated separately from SLE itself.

Brain and nerves

The 2010 EULAR recommendations on neuropsychiatric SLE list cerebrovascular disease and seizures as common, with a cumulative incidence above 5%, and severe cognitive dysfunction, major depression, acute confusional state, peripheral nerve disorders and psychosis as relatively uncommon, at 1 to 5%. Antiphospholipid antibodies raise the risk of cerebrovascular disease, seizures and chorea at least fivefold, and previous or current severe neuropsychiatric lupus raises the risk of cognitive dysfunction and seizures. The work-up is the same as in someone without SLE and aims to exclude other causes first: cerebrospinal fluid analysis to rule out infection, EEG for seizures, neuropsychological testing for cognition, nerve conduction studies for neuropathy and MRI. Inflammatory presentations are treated with glucocorticoids and immunosuppression, and the 2026 BSR guideline names intravenous cyclophosphamide, rituximab or both for active non-thrombotic disease, while antiphospholipid-related thrombotic events call for antiplatelet or anticoagulant treatment.

How are SLE disease activity and flares measured?

Disease activity in SLE is measured with validated indices, and the 2026 BSR guideline recommends the BILAG-2004 index or the SLEDAI-2K, with activity then categorised as absent, mild, moderate or severe and flares recorded. The SLEDAI-2K rates 24 items as present or absent over the previous 30 days, weighted by the type of manifestation but not its severity: arthritis of any severity scores 4 points and a rash 2. The maximum is 105, although scores above 20 are uncommon. It is quick but cannot capture partial improvement and scores some serious problems, such as haemolytic anaemia, low or not at all. The BILAG-2004 index instead grades 97 items in 9 organ domains over the past 4 weeks, each domain from A, highly active and likely to need more treatment, to E, no current or previous activity, so it tracks change within an organ. Both tools count only features attributed to SLE, and the guideline warns that inexperienced users tend to over-score mimics such as rosacea or osteoarthritis.

24items in the SLEDAI-2K, rated present or absent
105maximum SLEDAI-2K score; above 20 is uncommon
9organ domains in the BILAG-2004 index, graded A to E
12–24months between systematic damage assessments (BSR)
The two activity indices the 2026 BSR guideline recommends, and how often it asks for damage to be assessed.

Laboratory trends support the clinical picture without replacing it. The BSR guideline notes that rising anti-dsDNA and falling complement are associated with an impending flare, particularly in lupus nephritis. Yet in a classic study of 202 people followed for a median of 86.5 months, published in Arthritis & Rheumatism in 1996, fluctuations in blood counts, ESR, DNA binding and C3 and C4 were poor predictors of the 83 flares that occurred. A changing result is a reason to look closely, not a flare in itself.

Remission, low disease activity and damage

The BSR guideline makes remission the primary treatment goal, or the Lupus Low Disease Activity State (LLDAS) if remission is not possible, in a treat-to-target approach. LLDAS, defined in 2016, means a SLEDAI-2K of 4 or less with no activity in major organs (kidney, central nervous system, heart and lungs, vasculitis or fever) and no haemolytic anaemia or gut involvement, no new activity, a physician global assessment of 1 or less on a 0 to 3 scale, a low steroid dose and stable, well-tolerated maintenance treatment. People who spent more than half their follow-up in LLDAS accrued significantly less organ damage. The 2021 DORIS definition of remission is stricter: a clinical SLEDAI of 0, an evaluator's global assessment below 0.5, a steroid dose at or below a low ceiling and stable antimalarials, immunosuppressants and biologics. Damage, the irreversible part, is scored separately with the SLICC/ACR damage index, which records damage whatever its cause.

The exact wording of these definitions decides whether someone counts as in remission, so they are worth checking at the source. Ask AskMed how LLDAS differs from DORIS remission, or whether a persistent rash still scores on the SLEDAI-2K, and the answer quotes each definition with a link to the paper that set it.

Compare lupus activity and remission definitions in AskMed:

How should SLE be monitored over time?

Monitoring in SLE follows disease activity: the 2026 BSR guideline says people with active disease should be reviewed at least every 1 to 3 months, with blood pressure, urinalysis, renal function including proteinuria, anti-dsDNA antibodies, complement levels, inflammatory markers, a full blood count and liver function tests, plus further tests as needed. People with stable low disease activity or in remission can be seen less often, but at least every 12 months for adults and every 6 months for children. Urinalysis, blood pressure and body weight belong at every visit, and damage should be assessed systematically every 12 to 24 months. Monitoring also covers treatment, since immunosuppressants and biologics need regular laboratory checks under their own drug-monitoring guidance, and the long-term risks of the disease itself. The 2010 EULAR monitoring recommendations cover the same ground: cardiovascular risk, osteoporosis, cancer, infection, kidney and skin involvement, neuropsychological problems and eye assessment.

When to get urgent care

Infection has to be suspected first when someone with SLE has a fever, particularly when CRP is raised, as the authors of the 2019 criteria stress. Go to an emergency department or call emergency services for fever or feeling very unwell while taking immunosuppressants, chest pain or breathlessness, a seizure, new confusion or sudden weakness, or a painful swollen leg in someone with antiphospholipid antibodies. Contact the rheumatology team the same day for foamy urine, new swelling of the legs or around the eyes, much less urine than usual, or unusual bruising or bleeding.

Frequently asked questions

Can you have SLE with a negative ANA?

Rarely. ANA is present in 95 to 99% of people with SLE at some point, so a negative test makes SLE unlikely. Results can fluctuate, though, so a negative test does not rule out SLE after past positives, and a small persistently ANA-negative group exists that the 2019 criteria cannot classify. In children with lupus-like symptoms and a negative ANA, the BSR advises considering monogenic lupus and complement deficiencies.

What score confirms SLE on the EULAR/ACR criteria?

No score confirms it. A total of 10 or more points with at least one clinical item, after a positive ANA, classifies SLE for research. Diagnosis remains a clinical judgement by an experienced specialist, and the BSR guideline says the criteria can guide that judgement but are not diagnostic criteria.

Does a high anti-dsDNA mean a lupus flare is coming?

Not on its own. Rising anti-dsDNA together with falling C3 and C4 is associated with an impending flare, particularly in lupus nephritis, which is why both are monitored. But a 1996 study found that changes in laboratory tests were poor predictors of flares, so results are read alongside symptoms, examination and urine tests.

How often does someone with SLE need blood and urine tests?

It depends on activity. The 2026 BSR guideline advises review at least every 1 to 3 months during active disease, and at least every 12 months for adults (6 months for children) when the disease is stable or in remission. Urinalysis and blood pressure are checked at every visit.

What is the difference between disease activity and damage in SLE?

Activity is current, potentially reversible inflammation, measured with the SLEDAI-2K or BILAG-2004. Damage is irreversible organ change, recorded with the SLICC/ACR damage index whatever its cause. The BSR guideline asks for damage to be assessed every 12 to 24 months, because accumulated damage is linked to worse function, quality of life and survival.

Sources

  1. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71(9):1400-1412. Also in Ann Rheum Dis. 2019;78(9):1151-1159; full text.
  2. Aringer M, Leuchten N, Johnson SR. New Criteria for Lupus. Curr Rheumatol Rep. 2020;22(6):18.
  3. Md Yusof MY, Smith EMD, Lythgoe H, et al. The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus. Rheumatology (Oxford). 2026;65(6):keag223.
  4. Scopes J, Md Yusof MY. Challenges in the diagnosis of systemic lupus erythematosus. Clin Med (Lond). 2025;25(5):100509.
  5. Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29.
  6. Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint EULAR/ERA-EDTA recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713-723.
  7. Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis. Kidney Int. 2018;93(4):789-796.
  8. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42(4):599-608.
  9. Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations. Ann Rheum Dis. 2010;69(12):2074-2082.
  10. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.
  11. Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016;75(9):1615-1621.
  12. van Vollenhoven RF, Bertsias G, Doria A, et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med. 2021;8(1):e000538.
  13. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the SLICC/ACR damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39(3):363-369.
  14. Esdaile JM, Abrahamowicz M, Joseph L, et al. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum. 1996;39(3):370-378.
  15. Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010;69(7):1269-1274.
  16. National Institute of Diabetes and Digestive and Kidney Diseases. Lupus Nephritis.

Cited medical answers
you can trust.

AskMed on iPhone, iPad, Android and the web.